Associations of Antidiabetic Drugs with Diabetic Retinopathy in People with Type 2 Diabetes: an Umbrella Review and Meta-analysis

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Jan 19

PMID 38239984

Authors

Luyuan Tan

Zhaonan Wang

Kelvin Okoth

Konstantinos A Toulis

Alastair K Denniston

Baldev M Singh

Francesca L Crowe

Christopher Sainsbury

Jingya Wang

Krishnarajah Nirantharakumar

Affiliations

Soon will be listed here.

Abstract

Background: Diabetic retinopathy (DR) is the most frequent complication of type 2 diabetes and remains the leading cause of preventable blindness. Current clinical decisions regarding the administration of antidiabetic drugs do not sufficiently incorporate the risk of DR due to the inconclusive evidence from preceding meta-analyses. This umbrella review aimed to systematically evaluate the effects of antidiabetic drugs on DR in people with type 2 diabetes.

Methods: A systematic literature search was undertaken in Medline, Embase, and the Cochrane Library (from inception till 17th May 2022) without language restrictions to identify systematic reviews and meta-analyses of randomized controlled trials or longitudinal studies that examined the association between antidiabetic drugs and DR in people with type 2 diabetes. Two authors independently extracted data and assessed the quality of included studies using the AMSTAR-2 (A MeaSurement Tool to Assess Systematic Reviews) checklist, and evidence assessment was performed using the GRADE (Grading of recommendations, Assessment, Development and Evaluation). Random-effects models were applied to calculate relative risk (RR) or odds ratios (OR) with 95% confidence intervals (CI). This study was registered with PROSPERO (CRD42022332052).

Results: With trial evidence from 11 systematic reviews and meta-analyses, we found that the use of glucagon-like peptide-1 receptor agonists (GLP-1 RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i), or dipeptidyl peptidase-4 inhibitors (DPP-4i) was not statistically associated with the risk of DR, compared to either placebo (RR: GLP-1 RA, 0.98, 0.89-1.08; SGLT-2i, 1.00, 95% CI 0.79-1.27; DPP-4i, 1.17, 0.99-1.39) or other antidiabetic drugs. Compared to other antidiabetic drugs, meglitinides (0.34, 0.01-8.25), SGLT-2i (0.73, 0.10-5.16), thiazolidinediones (0.92, 0.67-1.26), metformin (1.15, 0.81-1.63), sulphonylureas (1.24, 0.93-1.65), and acarbose (4.21, 0.44-40.43) were not statistically associated with the risk of DR. With evidence from longitudinal studies only, insulin was found to have a higher risk of DR than other antidiabetic drugs (OR: 2.47, 95% CI: 2.04-2.99).

Conclusion: Our results indicate that antidiabetic drugs are generally safe to prescribe regarding the risk of DR among people with type 2 diabetes. Further robust and large-scale trials investigating the effects of insulin, meglitinides, and acarbose on DR are warranted.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=332052, identifier CRD42022332052.

Citing Articles

Impact of duration of treatments with metformin and sulfonylureas, individually or in combination, on diabetic retinopathy among newly diagnosed type 2 diabetic patients: a pooled cohort's analysis.

Bahardoust M, Mehrabi Y, Hadaegh F, Khalili D, Delpisheh A Int J Retina Vitreous. 2025; 11(1):9.

PMID: 39891223 PMC: 11784098. DOI: 10.1186/s40942-025-00637-w.

Diabetes Renders Photoreceptors Susceptible to Retinal Ischemia-Reperfusion Injury.

Antonetti D, Lin C, Shanmugam S, Hager H, Cao M, Liu X Invest Ophthalmol Vis Sci. 2024; 65(13):46.

PMID: 39570639 PMC: 11585066. DOI: 10.1167/iovs.65.13.46.

Forecasting the Pharmacological Mechanisms of and in Diabetic Retinopathy Treatment: A Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation Study.

Sahu N, Tyagi R, Kumar N, Mujeeb M, Akhtar A, Alam P Biology (Basel). 2024; 13(9).

PMID: 39336159 PMC: 11429473. DOI: 10.3390/biology13090732.

Repurposing metabolic regulators: antidiabetic drugs as anticancer agents.

Dhas Y, Biswas N, M R D, Jones L, Ashili S Mol Biomed. 2024; 5(1):40.

PMID: 39333445 PMC: 11436690. DOI: 10.1186/s43556-024-00204-z.

References

Andreadis P, Karagiannis T, Malandris K, Avgerinos I, Liakos A, Manolopoulos A . Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Obes Metab. 2018; 20(9):2255-2263. DOI: 10.1111/dom.13361. View

Pollock M, Fernandes R, Newton A, Scott S, Hartling L . The impact of different inclusion decisions on the comprehensiveness and complexity of overviews of reviews of healthcare interventions. Syst Rev. 2019; 8(1):18. PMC: 6329144. DOI: 10.1186/s13643-018-0914-3. View

Bethel M, Diaz R, Castellana N, Bhattacharya I, Gerstein H, Lakshmanan M . HbA Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression. Diabetes Care. 2021; 44(1):290-296. PMC: 7783944. DOI: 10.2337/dc20-1815. View

Wang F, Mao Y, Wang H, Liu Y, Huang P . Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. Clin Drug Investig. 2021; 42(1):17-28. DOI: 10.1007/s40261-021-01110-w. View

Drucker D . Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018; 27(4):740-756. DOI: 10.1016/j.cmet.2018.03.001. View

Tang H, Li G, Zhao Y, Wang F, Gower E, Shi L . Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis. Diabetes Obes Metab. 2018; 20(5):1262-1279. DOI: 10.1111/dom.13232. View

Dicembrini I, Nreu B, Scatena A, Andreozzi F, Sesti G, Mannucci E . Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2017; 54(10):933-941. DOI: 10.1007/s00592-017-1031-9. View

El Mouhayyar C, Riachy R, Khalil A, Eid A, Azar S . SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review. Int J Endocrinol. 2020; 2020:1762164. PMC: 7066394. DOI: 10.1155/2020/1762164. View

Li Y, Ryu C, Munie M, Noorulla S, Rana S, Edwards P . Association of Metformin Treatment with Reduced Severity of Diabetic Retinopathy in Type 2 Diabetic Patients. J Diabetes Res. 2018; 2018:2801450. PMC: 5952500. DOI: 10.1155/2018/2801450. View

10.

Mulvihill E, Drucker D . Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014; 35(6):992-1019. PMC: 7108477. DOI: 10.1210/er.2014-1035. View

11.

Guyatt G, Oxman A, Akl E, Kunz R, Vist G, Brozek J . GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011; 64(4):383-94. DOI: 10.1016/j.jclinepi.2010.04.026. View

12.

Lee C, Kim Y, Cho H, Park J, Jeong H, Lee S . Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation. Sci Rep. 2016; 6:29393. PMC: 4933943. DOI: 10.1038/srep29393. View

13.

Douros A, DellAniello S, Yu O, Filion K, Azoulay L, Suissa S . Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ. 2018; 362:k2693. PMC: 6050517. DOI: 10.1136/bmj.k2693. View

14.

Ogurtsova K, Guariguata L, Barengo N, Ruiz P, Sacre J, Karuranga S . IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021. Diabetes Res Clin Pract. 2021; 183:109118. DOI: 10.1016/j.diabres.2021.109118. View

15.

M Jingi A, Noubiap J, Essouma M, Bigna J, Nansseu J, Ellong A . Association of insulin treatment versus oral hypoglycaemic agents with diabetic retinopathy and its severity in type 2 diabetes patients in Cameroon, sub-Saharan Africa. Ann Transl Med. 2016; 4(20):395. PMC: 5107390. DOI: 10.21037/atm.2016.08.42. View

16.

Ahmad E, Lim S, Lamptey R, Webb D, Davies M . Type 2 diabetes. Lancet. 2022; 400(10365):1803-1820. DOI: 10.1016/S0140-6736(22)01655-5. View

17.

Li J, Hung Y, Bair H, Hsu S, Hsu C, Lin C . Sodium-glucose co-transporter 2 inhibitor add-on therapy for metformin delays diabetic retinopathy progression in diabetes patients: a population-based cohort study. Sci Rep. 2023; 13(1):17049. PMC: 10564914. DOI: 10.1038/s41598-023-43893-2. View

18.

Possidente C, Fanelli G, Serretti A, Fabbri C . Clinical insights into the cross-link between mood disorders and type 2 diabetes: A review of longitudinal studies and Mendelian randomisation analyses. Neurosci Biobehav Rev. 2023; 152:105298. DOI: 10.1016/j.neubiorev.2023.105298. View

19.

Hex N, Bartlett C, Wright D, Taylor M, Varley D . Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012; 29(7):855-62. DOI: 10.1111/j.1464-5491.2012.03698.x. View

20.

Gargiulo P, Savarese G, DAmore C, De Martino F, Lund L, Marsico F . Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis. Nutr Metab Cardiovasc Dis. 2017; 27(12):1081-1088. DOI: 10.1016/j.numecd.2017.09.006. View